Replies to post #117706 on Biotech Values

[genisi]

I assume they (as jbog noted, most ex-US countries), will pay for the a new, expensive, treatment with xxx efficacy only if certain patients fail (or have a high risk of failing) the existing less expensive treatment with xx efficacy.

[jbog]

ThomasS,

They would pay something for the previous expensive treatment, but it wouldn't be what the manufacturer probably wanted. Many manufacturers will not sell at the prices offered.

I don't recall the drugs off-hand, but some of the newer bio's not only are reimbursed at a low price, but if the patients themselves don't benefit the money is refunded back to the governmant.